Gliclazid-Mepha Teva MR 30 mg, Retardtabletten - 30 Swissmedic Key 65694006 Registration Holder Mepha Pharma AG Name Gliclazid-Mepha Teva MR 30 mg, Retardtabletten Date of registration 17.09.2015 Introduction of Sequence 17.09.2015 ATC-Classification Gliclazide (A10BB09) Revision date WHO WHO-DDD Valid until Index Therapeuticus (BSV) 07.06.20. Show package size 30 Index Therapeuticus (Swissmedic) 07.06.20. Description Swissmedic categorie. B SL Eintrag No Indication Information for professionals IP Consumer information CI Ex-factory-Price PR Deductible k.A. Consumer price PR Feedback FB GTIN 7680656940061 Medication Code Synthetika Pharmacode Disponibility
Composition gliclazidum 30 mg, lactosum monohydricum 56.8 mg, hypromellosum, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, pro compresso. Packungsbestandteile Galenic Form Delayed release tablets Active Agent Dose Gliclazide 30 mg
Inactive agents Dose Cellulosum Microcristallinum Hypromellosum Lactose Monohydrate 56.8 mg Magnesii Stearas Pro Compresso Silica Colloidalis Anhydrica
Source Data was imported : 06.06.2025
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
